Headlines about Taro Pharmaceutical Industries (NYSE:TARO) have trended somewhat positive recently, Accern reports. Accern ranks the sentiment of news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Taro Pharmaceutical Industries earned a daily sentiment score of 0.21 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 45.991708350153 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
Taro Pharmaceutical Industries (NYSE TARO) traded up $0.61 on Friday, reaching $106.03. The company had a trading volume of 120,607 shares, compared to its average volume of 194,120. The company has a market cap of $4,280.00, a P/E ratio of 13.07 and a beta of 0.62. Taro Pharmaceutical Industries has a twelve month low of $94.00 and a twelve month high of $128.46.
Separately, BidaskClub downgraded Taro Pharmaceutical Industries from a “buy” rating to a “hold” rating in a research note on Thursday, October 12th.
Taro Pharmaceutical Industries Company Profile
Taro Pharmaceutical Industries Ltd. (Taro) is a science-based pharmaceutical company. The Company operates principally through three entities: Taro Pharmaceutical Industries Ltd. (Taro Israel), and two of its subsidiaries, Taro Pharmaceuticals Inc (Taro Canada) and Taro U.SA The Company markets over 200 pharmaceutical products in over 25 countries.
What are top analysts saying about Taro Pharmaceutical Industries? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Taro Pharmaceutical Industries and related companies.